Patentes farmacêuticas e acessibilidade aos medicamentos no Brasil

Marques, Marília Bernardes

doi:10.1590/s0104-59702000000200001

Cited by 19 publications

(13 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Currently, basic care uses the policy of pharmaceutical assistance (8) that incorporates the principle of integral assistance and access to medication, with quality on the coverage. It is an important link in the continuity of care for SUS clients -most of them have money restrictions.…”

Section: Resultsmentioning

confidence: 99%

Use and cost of medication in low risk pregnant women

Maeda

Secoli²

2008

Rev. Latino-Am. Enfermagem

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

Use and cost of medication in low risk pregnant women

Maeda

Secoli²

2008

Rev. Latino-Am. Enfermagem

View full text Add to dashboard Cite

“…O Brasil destaca-se por ser o país com maior biodiversidade mundial possuindo, de acordo com Marques (2000), 22% de todas as espécies biológicas do mundo. Dentro desse leque único de riquezas biológicas, o país também se destaca em outro aspecto no que diz respeito às plantas: as florestas brasileiras guardam um número significativo de espécies que têm fins terapêuticos e medicinais.…”

Section: (Recebido Em 5 De Dezembro De 2006 E Aprovado Em 25 De Junhounclassified

Levantamento etnobotânico e caracterização de plantas medicinais em fragmentos florestais de Dourados-MS

Alves

Mota²,

Soares

et al. 2008

Ciênc. agrotec.

View full text Add to dashboard Cite

RESUMOObjetivou-se, neste estudo, coletar e identificar espécies nativas consideradas medicinais em dois fragmentos florestais no município de Dourados-MS. Foram identificadas 37 espécies distribuídas em 28 famílias as quais foram indicadas pelos mateiros da região por serem utilizadas pela população como alternativa medicinal. Das famílias identificadas, as que apresentaram maior número de espécies foram Piperaceae (10,8%), Moraceae (8,1%), Smilaceae (8,1%), Myrtaceae (5,4%) e Rubiacee (5,4%). O levantamento etnobotânico indicou 45 diferentes usos medicinais para as espécies e as partes mais utilizadas para o preparo de remédios são as folhas e cascas, sendo que as doenças para as quais houve maior número de indicações foram reumatismo, disenteria, diabetes, febres, tosses e cicatrizações.Termos para indexação: Espécies nativas, medicina popular, conhecimento popular. ABSTRACTThe objective of this study was to collect and to identify native species considered medicinal in forest fragments in DouradosMato Grosso Sul. Had been identified 37 species distributed in 28 families which had been indicated by the woodsman of the region for being used by the population as medicinal alternative. Families that presented greater number of species were Piperaceae (10.8%), Moraceae (8.1%), Smilaceae (8.1%), Myrtaceae (5.4%) and Rubiacee (5.4%). The etnobotanical survey indicated 45 different medicinal uses for the species, the used parts more for the preparation of remedies is the leaves and bark, being that the illnesses for which bigger number of indications had been rheumatism, dysentery, diabetes, fevers, coughs and cicatrizations.

show abstract

“…The Brazilian government, at all its levels-federal, state, and municipalpurchases 35% of the entire national pharmaceutical production (55) and is the main buyer in this sector, having spent roughly US$ 2.1 billion on drugs in 2004. The government should thus develop initiatives, or improve existing ones, that focus on diseases of greater impact on public health, ones that consequently have a negative socioeconomic influence.…”

Section: Original Research Vidotti Et Al • New Drugs In Brazil and Pmentioning

confidence: 99%

“…In the former, most health research and some manufacturing is funded by and conducted within the public sector, and therefore, must be driven by public health needs (55,57,58).…”

Section: Health Priorities and Networkmentioning

confidence: 99%

New drugs in Brazil: do they meet Brazilian public health needs?

Vidotti¹,

Castro²,

Calil³

2008

Rev Panam Salud Publica

View full text Add to dashboard Cite

Objectives. To describe the new drugs marketed in Brazil during the period 2000-2004, compare Conclusions. A mismatch occurs between public health needs and the new drugs launched on the Brazilian market. Not only did the number of new drugs decrease in the study period, but only a few were actually new in therapeutic terms. Developing countries must acquire expertise in research and development to strengthen their capacity to innovate and produce the drugs they need.New drugs, drugs of interest in public health, pharmaceutical drug trade, innovation, pharmacoepidemiology, Brazil. ABSTRACTResearch and development (R&D) are essential to generating health products that combat diseases. R&D conducted by the pharmaceutical industry addresses the needs of wealthier countries, but all too often, underprivileged populations in poorer areas of the world have few or no treatment options and restricted access to treatments that do exist. The power held by the pharmaceutical industry is, to varying degrees, lost when the market is insufficiently wide or steady, or when effective public policies are not in place to promote R&D. Given this context, the current situation regarding the launching of new drugs needs to be acknowledged and addressed by policymakers, managers, and researchers in public and private institutions alike, if availability for actual public health needs is to be improved.

show abstract

Patentes farmacêuticas e acessibilidade aos medicamentos no Brasil

Cited by 19 publications

References 18 publications

Use and cost of medication in low risk pregnant women

Use and cost of medication in low risk pregnant women

Levantamento etnobotânico e caracterização de plantas medicinais em fragmentos florestais de Dourados-MS

New drugs in Brazil: do they meet Brazilian public health needs?

Contact Info

Product

Resources

About